A5005302465- Ovarian cancer diagnosis and treatment
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research
- Iron Metabolism and Disorders
- Erythropoietin and Anemia Treatment
- Heart Failure Treatment and Management
- Ferroptosis and cancer prognosis
- Intraperitoneal and Appendiceal Malignancies
- Colorectal and Anal Carcinomas
- Barrier Structure and Function Studies
- Gastric Cancer Management and Outcomes
China-Japan Friendship Hospital
2025
Beijing University of Chinese Medicine
2025
Ruijin Hospital
2023
Southeast University
2022-2023
Background Heart failure (HF) guidelines recommend routine testing for iron deficiency (ID) and, those with ID, intravenous if the left ventricular ejection fraction is <50%. Guideline adherence to these recommendations by cardiologists in China unknown. Methods and results An independent academic web-based survey was designed distributed via social networks across China. Overall, 1342 (median age 34 years, IQR 30–39, 51% women) from all provinces of completed this survey. More than half...
Patients (363 in total) with stomach adenocarcinoma from The Cancer Genome Atlas (TCGA) cohort were included. An autoencoder was constructed to integrate the RNA sequencing, miRNA and methylation data. features of bottleneck layer used perform k-means clustering algorithm obtain different subgroups for evaluating prognosis-related risk adenocarcinoma. model's robustness verified using a 10-fold cross-validation (CV). Survival analyzed by Kaplan-Meier method. Univariate multivariate Cox...
Anlotinib is a novel oral small-molecule multi-target tyrosine kinase inhibitor that has been approved for treating non-small cell lung cancer. However, its efficacy and safety among patients with advanced gynecological cancer have not comprehensively evaluated. We conducted this study to address issue in the real-world setting.Data from treated persistent, recurrent or metastatic were collected 17 centers August 2018. The database lock-time was on March 2022. administered orally days 1-14...
5608 Background: Anlotinib is a novel oral small-molecule multi-target tyrosine kinase inhibitor that has been approved for treating non-small cell lung cancer. However, its efficacy and safety among patients with advanced gynecological We conducted this study to address issue in the real-world setting. Methods: Data from treated anlotinib persistent, recurrent or metastatic cancer including cervical, endometrial, ovarian were collected 17 centers August 2018. The database lock-time was on...